Bliss Gvs Pharma Limited · NSE:BLISSGVS
Bliss Gvs Pharma — Q3 FY2019 Earnings Presentation
18 slides from Bliss Gvs Pharma's earnings presentation, Feb 1, 2019
Slide 1: Bliss GVS Pharma exchange filing cover letter
BLISS GVS PHARMA LTO. February 01, 2019 To To The Manager, Listing Deparhnent The General Manager, Listing Department National Stock Exchange of India BSE Limited Plot no. c/i G Block, Phiroze Jeejeebhoy Towers, Bandra-Kurla Complex, Bandra (East), Dalal Street, Mumbai- 400 051 Mumbai- 400 001 Symbo
Slide 2: Earnings Presentation 9M/Q3-FY19
EARNINGS PRESENTATION 9M/Q3-FY19
Slide 3: Executive Summary
Executive Summary OVERVIEW Incorporated in 1984, Bliss GVS Pharma Ltd., has more than 34 years of expertise in manufacturing, marketing & exporting of more than 250 Branded Formulations in various dosage forms with a major focus on the Sub-Sahara African region. It is a world leader in Supposito
Slide 4: 9M/Q3-FY19 Financial Highlights
9M/Q3-FY19 Financial Highlights Q3-FY19 Performance (Standalone): 9M-FY19 Performance (Standalone): • Operational Income : INR 956 Mn; Growth of 29.9% • Operational Income : INR 3,205 Mn; Growth of YoY 49.1% YoY • EBITDA : INR 246 Mn; Growth of 24.9% YoY • EBITDA : INR 792 Mn; Growth of 31.8% Yo
Slide 5: Q3-FY19 Operational Highlights
Q3-FY19 Operational Highlights Standalone - Operational Highlights Increase in standalone operational revenue by INR 220 Mn (30%) was on account of increase in the export business (17%) mainly to Nigeria, Ghana, France, DR Congo and Kenya etc. along with increase in domestic sales from Q3-FY18 to
Slide 6: Quarterly - Standalone Income Statement (Ind-AS)
Quarterly - Standalone Income Statement (Ind-AS) PARTICULARS (INR Mn) Q3-FY19 Q3-FY18 Y-o-Y Q2-FY19 Q-o-Q Operational Revenue 956 736 29.9% 1,200 (20.3)% Total Expenses 710 539 31.7% 924 (23.2)% EBITDA 246 197 24.9% 276 (10.9)% EBITDA Margins (%) 25.73% 26.77% (104)Bps 23.00% 273Bps Depreciation 13
Slide 7: Quarterly - Standalone Financial Highlights
Quarterly - Standalone Financial Highlights Operational Revenue (INR Mn) EBITDA (INR Mn) 350 1300 300 1000 250 200 700 150 400 100 736 956 197 246 100 50 Q3-FY18 Q3-FY19 Q3-FY18 Q3-FY19 PAT (INR Mn) EBITDA Margins & PAT Margins (%) EBITDA Margins PAT Margins 130 120 35% 110 100 25% 27% 26% 90 80 15%
Slide 8: YTD - Standalone Income Statement (Ind-AS)
YTD - Standalone Income Statement (Ind-AS) PARTICULARS (INR Mn) 9M-FY19 9M-FY18 Y-o-Y Operational Revenue 3,205 2,150 49.1% Total Expenses 2,413 1,549 55.8% EBITDA 792 601 31.8% EBITDA Margins (%) 24.71% 27.95% (324)Bps Depreciation 43 42 2.4% Finance Cost 25 54 (53.7)% Other Income 328 67 NA PBT 1,
Slide 9: Quarterly - Consolidated Income Statement (Ind-AS)
Quarterly - Consolidated Income Statement (Ind-AS) PARTICULARS (INR Mn) Q3-FY19 Q3-FY18* Y-o-Y Q2-FY19 Q-o-Q Operational Revenue 2,204 1,959 12.5% 2,284 (3.5)% Total Expenses 1,768 1,479 19.5% 1,869 (5.4)% EBITDA 436 480 (9.2)% 415 5.1% EBITDA Margins (%) 19.78% 24.50% (472)Bps 18.17% 161Bps Depreci
Slide 10: YTD - Consolidated Income Statement (Ind-AS)
YTD - Consolidated Income Statement (Ind-AS) PARTICULARS (INR Mn) 9M-FY19 9M-FY18* Y-o-Y Operational Revenue 6,542 6,480 1.0% Total Expenses 5,285 4,884 8.2% EBITDA 1,257 1,596 (21.2)% EBITDA Margins (%) 19.21% 24.63% (542)Bps Depreciation 67 165 (59.4)% Finance Cost 35 174 (79.9)% Other Income 348
Slide 11: Historical Standalone Income Statement
Historical Standalone Income Statement PARTICULARS (INR Mn) FY15 FY16 FY17* FY18* Operational Revenue 3,130 3,264 3,503 2,983 Total Expenses 2,268 2,299 2,493 2,098 EBITDA 862 965 1,010 885 EBITDA Margins (%) 27.54% 29.56% 28.83% 29.67% Depreciation 51 59 56 57 Finance Cost 112 135 91 70 Other Incom
Slide 12: Standalone Balance Sheet (Ind-AS)
Standalone Balance Sheet (Ind-AS) PARTICULARS (INR Mn) FY17 FY18 H1-FY19 PARTICULARS (INR Mn) FY17 FY18 H1-FY19 EQUITIES & LIABILITIES ASSETS Non-current Assets 1,115 1,201 1,392 Shareholder Funds 4,916 5,414 5,871 (A) Property, Plant and Equipment 750 720 729 (A) Share Capital 103 103 103 (B) Capit
Slide 13: Historical Consolidated Income Statement
Historical Consolidated Income Statement PARTICULARS (INR Mn) FY15 FY16 FY17* FY18* Operational Revenue 4,071 5,469 8,024 8,151 Total Expenses 3,037 3,912 5,996 6,180 EBITDA 1,034 1,557 2,028 1,971 EBITDA Margins (%) 25.40% 28.47% 25.27% 24.18% Finance Costs 113 133 202 214 Depreciation and Amortisa
Slide 14: Consolidated Balance Sheet (Ind-AS)
Consolidated Balance Sheet (Ind-AS) PARTICULARS (INR Mn) FY17 FY18 H1-FY19 PARTICULARS (INR Mn) FY17 FY18 H1-FY19 EQUITIES & LIABILITIES ASSETS Shareholder Funds 4,866 5,362 6,053 Non-current Assets 4,570 1,726 1,954 (A) Share Capital 103 103 103 (A) Property, Plant and Equipment 2,549 1,263 1,293 (
Slide 15: Standalone Financial Highlights
Standalone Financial Highlights Operational Revenue (INR Mn) EBITDA (INR Mn) & EBITDA Margins PAT (INR Mn) & PAT Margins 4,000 1200 800 30% 29% 30% 3,500 1000 700 25% 3,000 800 600 19% 20% 2,500 18% 16% 2,000 600 500 1,500 400 400 1,000 500 200 300 3,264 3,503 2,983 3,205 965 1,010 885 792 656 591 5
Slide 16: Consolidated Financial Highlights
Consolidated Financial Highlights Operational Revenue (INR Mn) EBITDA (INR Mn) & EBITDA Margins PAT (INR Mn) & PAT Margins 10,000 2,500 1,200 28% 25% 24% 8,000 2,000 1,000 19% 6,000 1,500 800 16% 14% 14% 4,000 1,000 600 11% 2,000 500 400 5,469 8,024 8,151 6,542 1,557 2,028 1,971 1,257 825 1,127 887
Slide 17: Market Data
Market Data Share Price Data as on 31st December, 2018 Bliss GVS Pharma Sensex 20% 10% 0% -10% -20% -30% -40% -50% Jan-18 Feb-18 Mar-18 Apr-18 May-18 Jun-18 Jul-18 Aug-18 Sep-18 Oct-18 Nov-18 Dec-18 Shareholding th Price Data (31st December, 2018) INR ShareholdingPattern Patternas ason on30 31stJune
Slide 18: Disclaimer
Disclaimer No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all events not current after the d